Results 61 to 70 of about 482,699 (357)

Non-Linear Self Augmentation Deep Pipeline for Cancer Treatment outcome Prediction [PDF]

arXiv, 2023
Immunotherapy emerges as promising approach for treating cancer. Encouraging findings have validated the efficacy of immunotherapy medications in addressing tumors, resulting in prolonged survival rates and notable reductions in toxicity compared to conventional chemotherapy methods.
arxiv  

Developments in Cancer Immunotherapy [PDF]

Digestive Diseases, 2010
Significant advances have been made in the field of cancer immunology and immunotherapy over the last three decades. An important step forward was the identification of human cancer antigens eliciting spontaneous immune responses in cancer patients. The most immunogenic human cancer antigens known to date belong to the cancer-testis family of antigens,
van den Broek, M, von Boehmer, L, Knuth, A   +2 more
openaire   +3 more sources

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Feasibility of radical cardiac‐sparing, treatment planning strategies for patients with locally advanced, non‐small cell lung cancer

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non‐small cell lung cancer (NSCLC) patients in order to minimize cardiac dose without compromising target coverage goals. Methods Retrospective analysis was performed for 20 NSCLC patients prescribed to 60–66 Gy that received a ...
Joshua P. Kim, Jake Dewalt, Aharon Feldman, Khaled Adil, Benjamin Movsas, Indrin J. Chetty   +5 more
wiley   +1 more source

Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence

Frontiers in Immunology
Chimeric antigen receptor (CAR)-T cell therapy is an effective treatment for hematological cancers; however, challenges remain in its application to solid tumors. Among these, the control of CAR-T cell exhaustion is important.
Taku Kouro, Taku Kouro, Daisuke Hoshino, Yasunobu Mano, Yasunobu Mano, Shoutaro Tsuji, Hidetomo Himuro, Hidetomo Himuro, Kohzoh Imai, Tetsuro Sasada, Tetsuro Sasada   +10 more
doaj   +1 more source

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]

, 2004
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core   +1 more source

Immunotherapy for bladder cancer

Research and Reports in Urology, 2015
It is nearly 40 years since Bacillus Calmette-Guérin (BCG) was first used as an immunotherapy to treat superficial bladder cancer. Despite its limitations, to date it has not been surpassed by any other treatment. As a better understanding of its mechanism of action and the clinical response to it have evolved, some of the questions around optimal ...
James S.A. Green, Nikhil Vasdev, Oliver Fuge, Paula Allchorne   +3 more
openaire   +6 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Journal for ImmunoTherapy of Cancer, 2016
Background Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor.
Michael Papamichail, Panagiotis Tzonis, Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Sonia A. Perez, Constantin N. Baxevanis   +5 more
doaj   +1 more source

Label-free Raman spectroscopy and machine learning enables sensitive evaluation of differential response to immunotherapy [PDF]

arXiv, 2020
Cancer immunotherapy provides durable clinical benefit in only a small fraction of patients, particularly due to a lack of reliable biomarkers for accurate prediction of treatment outcomes and evaluation of response. Here, we demonstrate the first application of label-free Raman spectroscopy for elucidating biochemical changes induced by immunotherapy ...
arxiv